MARKET WIREReuters • 3h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
Why ICUI Stock advanced +1.36% Today — RQD Quant Desk Flash
$168.65 +1.36% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $168.74
ICU Medical Inc. (ICUI) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $4.22B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ICUI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ICUI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, ICU Medical Inc. (NASDAQ: ICUI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $168.65 (+1.36% 1D, market cap $4.22B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, ICUI ranks #278 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ICUI compare to IRTC and PLSE in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), ICUI carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of 36.8%, and ROIC of 1.0%. By comparison, IRTC (iRhythm Holdings Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -13.5%, cap $4.21B) and PLSE (Pulse Biosciences Inc) posts a D- grade (41/100 RQD, P/E N/A, ROIC -30.7%, cap $3.96B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ICUI?
▼
Per ICUI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000883984), ICU Medical Inc. generated $2.23B in revenue (-6.3% YoY), $732.0K in net income, and $91.8M in free cash flow against $4.05B in total assets and $1.27B in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $168.73 (+0.05%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 4.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C+
Each axis scored 0–20
12M PRICE TARGET CONE-1.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICUI)Realized 20D OHLCV Swing Band: ±6.5%
Deterministic 5-Pillar Attribution (55/100 Composite)
🔍 WHY ICUI SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (22% of score)
FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 50.1 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$160.32+1.7% Next Q
47
Q2 (-2Q)Grade C-$162.99+2.2% Next Q
50
Q3 (-1Q)Grade C-$166.62+1.2% Next Q
52
CurrentGrade D+$168.65-0.5% Hist 90D α
55
Trajectory: D (47) → D+ (55)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the ICUI Bull Thesis Could Fail
Even with a 55/100 (D+) score, ICUI faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-0.68% YoY Shares) — any gross margin slip below 34.3% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($164.22) or 200D SMA ($148.59) invalidates the momentum regime and cuts Target Base ($166.37) toward Bear Floor ($129.77).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICUI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ICUI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ICUI Stock advanced +1.36% Today — RQD Quant Desk Flash
ICU Medical Inc. (ICUI) advanced +1.36% to $168.65, trading at 70% of its 52-week range ($113.37 – $192.85). Stretched risk/reward at current multiples (1% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 70% of its 52-week range ($113.37 – $192.85) with RSI-14 at 50.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.5% around $168.65 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 36.8% gross margin and $91.8M annual free cash flow.
Live ICUI Headlines & Catalysts
MARKET WIREReuters • 3h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 5h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 6h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 8h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 9h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 10h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 12h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ICUI)
- ✓Walkthrough of ICUI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ICUI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +41.48%▲ ASCENDING CHANNEL
2026-10-30O $169.6H $170.0L $163.2C $168.7VOL 216.6K
RES: $225.8SUP: $158.1SMA50: $164.2SMA200: $148.6
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ICUI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
40.6%/yr Implied 5Y Growth
vs. -6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ICUI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ICUI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ICUI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICUI)
Health Care Rank #278 of 1016
⚔️ IRTC vs ICUI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ICUI vs. IRTC, PLSE, NVST, HTFL)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ICU Medical Inc. (ICUI) ranks #278 by composite RQD confidence (55/100, grade D+) and #178 by equity capitalization ($4.22B). Within this direct 5-issuer industry benchmark cohort, NVST leads on earnings valuation at 84.1x trailing P/E, while NVST leads on capital efficiency and profitability with 5.1% ROIC and 54.7% gross margin. ICUI currently leads its immediate peer cohort in composite quantitative strength at 55/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ICUI
ACTIVE
ICU Medical Inc. | D+ | 55/100 | — | 36.8% | 1.0% | +1.36% | $4.22B | Benchmark Subject |
| IRTC iRhythm Holdings Inc. | D | 48/100 | — | 70.6% | -13.5% | +3.07% | $4.21B | /irtc-vs-icui → |
| PLSE Pulse Biosciences Inc | D- | 41/100 | — | -30.0% | -30.7% | +3.37% | $3.96B | /plse-vs-icui → |
| NVST Envista Holdings Corporation | D | 49/100 | 84.1x | 54.7% | 5.1% | +2.80% | $3.95B | /nvst-vs-icui → |
| HTFL Heartflow Inc. | D+ | 53/100 | — | 76.8% | -12.0% | +2.42% | $5.26B | /htfl-vs-icui → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000883984In its most recent audited fiscal period (FY2025, filed 2025-12-31), ICU Medical Inc. (ICUI) reported GAAP revenue of $2.23B (-6.3% vs. FY2024 revenue of $2.38B , and -1.2% cumulative change since FY2023) , GAAP net income of $732.0K, operating cash flow of $179.8M, and free cash flow of $91.8M (-26.4% YoY). On the balance sheet, ICUI closed FY2025 with $4.05B in total assets against $1.27B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.23B | $732.0K | $179.8M | $91.8M | $4.05B | $1.27B |
| FY2024 (FY) | 2024-12-31 | $2.38B | -$117.7M | $204.0M | $124.7M | $4.20B | $1.53B |
| FY2023 (FY) | 2023-12-31 | $2.26B | -$29.7M | $166.2M | $166.2M | — | — |
3. ICUI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ICUI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, ICU Medical Inc. (NASDAQ: ICUI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $168.65 (+1.36% 1D, market cap $4.22B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, ICUI ranks #278 in composite RQD confidence.
How does ICUI compare to IRTC and PLSE in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), ICUI carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of 36.8%, and ROIC of 1.0%. By comparison, IRTC (iRhythm Holdings Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -13.5%, cap $4.21B) and PLSE (Pulse Biosciences Inc) posts a D- grade (41/100 RQD, P/E N/A, ROIC -30.7%, cap $3.96B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ICUI?
Per ICUI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000883984), ICU Medical Inc. generated $2.23B in revenue (-6.3% YoY), $732.0K in net income, and $91.8M in free cash flow against $4.05B in total assets and $1.27B in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ICUI trading relative to its 50-day, 200-day, and 52-week technical levels?
ICUI last traded at $168.65 (+1.36% on volume of 202,523 shares), positioning the stock +2.70% above its 50-day simple moving average ($164.22) and +13.50% above its 200-day simple moving average ($148.59). Across its 52-week range of $113.37 to $192.85, ICUI sits at the 69.6% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($157.69 to $179.61).
ICUI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ICUI stock moving today?
Why ICUI Stock advanced +1.36% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (1% return on capital) under elevated 10-year interest-rate pressure.